 |
Tackling the Controversies of Biologic Therapy in Rheumatoid Arthritis and Spondyloarthropathy: Application of Emerging Clinical Data Into Daily Treatment Decisions CME Paul P. Emery, MA, MD, FRCP, Chair; Josef S. Smolen, MD; Paul Ridker, MD, MPH, FACC, FAHA; Muhammad Asim Khan, MD, MACP, FRCP; Arthur Kavanaugh, MD Author Information and Disclosures Release Date: March 6, 2008; Valid for credit through March 6, 2009 | Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Tackling the Controversies of Biologic Therapy in Rheumatoid Arthritis and Spondyloarthropathy: Application of Emerging Clinical Data Into Daily Treatment Decisions" symposium held at the Westin Boston Waterfront in Boston, Massachusetts, on November 8, 2007.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details Contents of This CME Activity- Welcome & IntroductionPaul P. Emery, MA, MD, FRCPAvailable As: Slides/Audio | Slides/Transcript | Audio
- Changing Expectations in Rheumatoid Arthritis: Achieving Remission vs Clinical ImprovementJosef S. Smolen, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Beyond ACR Scores: Radiographic Inhibition Leads to Downstream Effects on Quality of Life and ProductivityPaul P. Emery, MA, MD, FRCPAvailable As: Slides/Audio | Slides/Transcript | Audio
- Inflammation and Cardiovascular Risk: Is There a Role for Anti-Inflammatory Therapy?Paul Ridker, MD, MPH, FACC, FAHAAvailable As: Slides/Audio | Slides/Transcript | Audio
- Optimal Management of the Spondyloarthropathies and Their Associated Comorbidities: What Have the Clinical Data Taught Us?Muhammad Asim Khan, MD, MACP, FRCPAvailable As: Slides/Audio | Slides/Transcript | Audio
- Are We Doing More Good Than Harm? A Benefit/Risk Analysis of Biologic Therapy in RAArthur Kavanaugh, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Point-Counterpoint -- A Roundtable Discussion & Debate of Key Issues in Patient Management of RA and SpAPaul P. Emery, MA, MD, FRCP, Josef S. Smolen, MD, Paul Ridker, MD, MPH, FACC, FAHA, Muhammad Asim Khan, MD, MACP, FRCP, Arthur Kavanaugh, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright ©2007 Scientific Frontiers, Inc. All rights reserved. |
|
|
Learning Objectives Upon completion of this activity, participants should be better able to - Compare and contrast the efficacy and safety of tumor necrosis factor (TNF) antagonists and other biologic agents in achieving remission and/or modifying the natural history of rheumatoid arthritis (RA), especially in halting radiographic progression of disease, preserving
function and quality of life, and improving productivity.
- Outline the latest clinical data suggesting that certain TNF antagonists may prevent endothelial dysfunction, the first step in the pathway to atherosclerosis and cardiovascular disease.
- Describe the latest clinical data showing the safety and efficacy of TNF antagonists in treating spondyloarthropathy (SpA), including extra-articular manifestations of disease.
- Define
the benefit/risk ratio for biologic agents used to treat patients with RA.
Authors and Disclosures Paul P. Emery, MA, MD, FRCP
Disclosure: Grant/Research Support, Consultant, Advisory Board, Honoraria: Abbott Josef S. Smolen, MD
Disclosure: Grant/Research Support, Consultant,
Advisory Board, Honoraria: Abbott, Bristol-Myers Squibb, Centocor, Roche, sanofi-aventis, Schering-Plough, Wyeth, UCB Paul Ridker, MD, MPH, FACC, FAHA
Disclosure: Grant/Research Support, Consultant: Abbott, Amgen, AstraZeneca, Dade-Behring
Dr Ridker is listed as a coinventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular
disease. Muhammad Asim Khan, MD, MACP, FRCP
Disclosure: Consultant, Speakers' Bureau, Advisory Board, Honoraria: Abbott, Amgen, Centocor, Schering-Plough, Wyeth Arthur Kavanaugh, MD
Disclosure: Grant/Research Support, Honoraria: Abbott, Amgen, Centocor, Biogen Idec, Genentech Inc., Bristol-Myers Squibb |
 |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Chicago Medical School at Rosalind Franklin University of Medicine & Science and Scientific Frontiers, Inc. The Chicago Medical School at Rosalind Franklin University of Medicine & Science is accredited by the ACCME to provide continuing medical
education for physicians.
The Chicago Medical School at Rosalind Franklin University of Medicine & Science designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
